Synthesis of N4-(substituted phenyl)-N4-alkyl/ desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines and identification of new microtubule disrupting compounds that are effective against multidrug resistant cells

Bioorganic and Medicinal Chemistry

Volumn 21, Issue 4, 2013, Pages 891-902

  Gangjee, Aleem ^a   Zaware, Nilesh ^a   Devambatla, Ravi Kumar Vyas ^a   Raghavan, Sudhir ^a   Westbrook, Cara D ^b,c   Dybdal Hargreaves, Nicholas F ^b,c   Hamel, Ernest ^d   Mooberry, Susan L ^b,c  

^a DUQUESNE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Microtubules; Multidrug resistance; Pyrimido 4,5 b indole 2,4 diamines

Indexed keywords

2 AMINO 6 HYDRAZINYLPYRIMIDIN 4(3H) ONE; ANILINE; COLCHICINE; COMBRETASTATIN A4; CYCLOHEXANONE; DIAMINE DERIVATIVE; N [4 [(3 BROMOPHENYL)AMINO] 9H PYRIMIDO[4,5 B]INDOL 2 YL] 2,2 DIMETHYLPROPANAMIDE; N [4 [(3 METHOXYPHENYL)(METHYL)AMINO] 9H PYRIMIDO[4,5 B]INDOL 2 YL] 2,2 DIMETHYLPROPANAMIDE; N [4 [(3 METHOXYPHENYL)AMINO] 9H PYRIMIDO [4,5 B]INDOLE 2 YL] 2,2 DIMETHYLPROPANAMIDE; N [4 [(4 METHOXYPHENYL)(METHYL)AMINO] 9H PYRIMIDO[4,5 B]INDOL 2YL] 2,2 DIMETHYLPROPANAMIDE; N [4 [(4 METHOXYPHENYL)AMINO] 9H PYRIMIDO[4,5 B]INDOL 2 YL] 2,2 DIMETHYLPROPANAMIDE; N4 (3 METHOXYPHENYL) 9H PYRIMIDO[4,5 B]INDOLE 2,4 DIAMINE; N4 (3 METHOXYPHENYL) N4 METHYL 9H PYRIMIDO[4,5 B]INDOLE 2,4 DIAMINE; N4 (3,4,5 TRIMETHOXYPHENYL) 9H PYRIMIDO[4,5 D]INDOLE 2,4 DIAMINE; N4 (4 ETHOXYPHENYL) N4 METHYL 9H PYRIMIDO[4,5 B]INDOLE 2,4 DIAMINE; N4 (4 METHOXYPHENYL) 9H PYRIMIDO[4,5 B]INDOLE 2,4 DIAMINE; N4 (4 METHOXYPHENYL) N4 METHYL 9H PYRIMIDO[4,5 B]INDOLE 2,4 DIAMINE; N4 ETHYL N4 (4 METHOXYPHENYL) 9H PYRIMIDO[4,5 B]INDOLE 2,4 DIAMINE; PACLITAXEL; PYRIMIDINE DERIVATIVE; PYRIMIDO[4,5 B]INDOLE 2,4 DIAMINE DERIVATIVE; PYRROLO[2,3 D]PYRIMIDINE; TUBULIN; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CHLORINATION; CONTROLLED STUDY; CYCLIZATION; DRUG POTENCY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MICROTUBULE; MICROTUBULE ASSEMBLY; MOLECULAR MODEL; MULTIDRUG RESISTANCE; OXIDATION; TUMOR CELL;

ANILINE COMPOUNDS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; CYCLIZATION; CYCLOHEXANONES; DIAMINES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MICROTUBULES; MOLECULAR DOCKING SIMULATION; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; TUBULIN MODULATORS;

EID: 84873299152     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2012.12.010     Document Type: Article

References (34)

1. Gangjee, A.; Zaware, N.; Devambatla, R. K. V.; Mooberry, S. L.; Hamel, E. From Abstracts of Papers, 242nd ACS National Meeting & Exposition, Aug 28-Sep 1, 2011; Denver, CO, United States, MEDI-53.
2. R.A. Stanton, K.M. Gernert, J.H. Nettles, and R. Aneja Med. Res. Rev. 31 2011 443
3. C. Dumontet, and M.A. Jordan Nat. Rev. Drug Disc. 9 2010 790
4. E. Komlodi-Pasztor, D. Sackett, J. Wilkerson, and T. Fojo Nat. Rev. Clin. Oncol. 8 2011 244
5. A. Jordan, J.A. Hadfield, N.J. Lawrence, and A.T. McGown Med. Res. Rev. 18 1998 259
6. J.J. Correia, and S. Lobert Curr. Pharm. Des. 7 2001 1213
7. D.W. Siemann, D.J. Chaplin, and P.A. Walicke Expert Opin. Invest. Drugs 18 2009 189
8. Q.S. Ng, V. Goh, D. Carnell, K. Meer, A.R. Padhani, M.I. Saunders, and P.J. Hoskin Int. J. Radiat. Oncol., Biol., Phys. 67 2007 1375
9. Selected clinical trials data for CA4P either alone or in combination: http://www.oxigene.com/pipeline/zybrestat-in-oncology/; Combretastatin A4 phosphate in treating patients with advanced solid tumors, http:// clinicaltrials.gov/ct2/show/NCT00003768?term=CA4P&rank=11; Combretastatin A4 phosphate in treating patients with advanced anaplastic thyroid cancer, http://clinicaltrials.gov/ct2/show/NCT00060242?term=CA4P&rank=9; A safety and efficacy study of carboplatin, paclitaxel, bevacizumab and CA4P in non-small cell lung cancer (FALCON), http://clinicaltrials.gov/ct2/show/NCT00653939?term= combretastatin&rank=8.
10. Clinical trials: A phase I clinical trial of OXi4503 for relapsed and refractory AML and MDS, http://clinicaltrials.gov/ct2/show/NCT01085656?term= CA1P&rank=1.
11. A.T. Fojo, and M. Menefee Semin. Oncol. 32 2005 S3
12. N. Kumar J. Biol. Chem. 256 1981 10435
13. G.D. Leonard, T. Fojo, and S.E. Bates Oncologist 8 2003 411
14. C. Lhomme, F. Joly, J.L. Walker, A.A. Lissoni, M.O. Nicoletto, G.M. Manikhas, M.M.O. Baekelandt, A.N. Gordon, P.M. Fracasso, W.L. Mietlowski, G.J. Jones, and M.H. Dugan J. Clin. Oncol. 26 2008 2674
15. M.F. Fromm Int. J. Clin. Pharmacol. Ther. 38 2000 69
16. M. Kavallaris, D.Y. Kuo, C.A. Burkhart, D.L. Regl, M.D. Norris, M. Haber, and S.B. Horwitz J. Clin. Invest. 100 1997 1282
17. M. Hari, H. Yang, C. Zeng, M. Canizales, and F. Cabral Cell Motil. Cytoskeleton 56 2003 45
18. P. Seve, and C. Dumontet Lancet Oncol. 9 2008 168
19. A. Gangjee, Y. Zhao, L. Lin, S. Raghavan, E.G. Roberts, A.L. Risinger, E. Hamel, and S.L. Mooberry J. Med. Chem. 53 2010 8116
20. A. Gangjee, J. Patel, R.L. Kisliuk, and Y. Gaumont J. Med. Chem. 35 1992 3678
21. M.C. Lubinu, L. De Luca, G. Giacomelli, and A. Porcheddu Chem. Eur. J. 17 2011 82
22. A.F. Abdel-Magid, K.G. Carson, B.D. Harris, C.A. Maryanoff, and R.D. Shah J. Org. Chem. 61 1996 3849
23. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd J. Natl. Cancer Inst. 82 1990 1107
24. M.R. Boyd, and K.D. Paull Drug Dev. Res. 34 1995 91
25. A.L. Risinger, E.M. Jackson, L.A. Polin, G.L. Helms, D.A. LeBoeuf, P.A. Joe, E. Hopper-Borge, R.F. Luduena, G.D. Kruh, and S.L. Mooberry Cancer Res. 68 2008 8881
26. E. Hamel, and C.M. Lin Biochemistry 23 1984 4173
27. E. Hamel Cell Biochem. Biophys. 38 2003 1
28. P. Verdier-Pinard, J.-Y. Lai, H.-D. Yoo, J. Yu, B. Marquez, D.G. Nagle, M. Nambu, J.D. White, J.R. Falck, W.H. Gerwick, B.W. Day, and E. Hamel Mol. Pharmacol. 53 1998 62
29. R.B.G. Ravelli, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, and M. Knossow Nature 428 2004 198
30. Molecular Operating Environment (MOE 2008.10); Chemical Computing Group, Inc.: Montreal, Quebec, Canada, 2008; www.chemcomp.com.
31. T.L. Nguyen, C. McGrath, A.R. Hermone, J.C. Burnett, D.W. Zaharevitz, B.W. Day, P. Wipf, E. Hamel, and R. Gussio J. Med. Chem. 48 2005 6107
32. E.C. Taylor, and A.J. Cocuzza J. Org. Chem. 44 1979 1125 1128
33. L. Lee, L.M. Robb, M. Lee, R. Davis, H. Mackay, S. Chavda, B. Babu, E.L. O'Brien, A.L. Risinger, S.L. Mooberry, and M. Lee J. Med. Chem. 53 2010 325
34. A. Krishan J. Cell Biol. 66 1975 188 193